#backgroundnoize

[gsradionewark]

*** NOW PLAYING *** NOW PLAYING *** .... ONLY ON GS RADIO NEWARK #OURRADIOSTATION. #gsradionewarknj. #gsradionewark 💿📀💽💿📀💽💿📀💽💿📀💽💿📀💽💿📀💽💿📀💽HOUSE / SOULFUL HOUSE MUSIC ... IT'S GOING DOWWWNNN #BACKGROUNDNOIZE ... POWERED BY: THE VOICE OF SOUL Dvs Imrealdvs Imaad LOG ON NOWWWWWWW @WWW.GSRADIONEWARK.COM #house #housemusic #housemusicalllifelong #soulful #soulfulhouse #soulfulhousemusic #gottahavehouse #gottahavehousemusic #loveandsoul #soulfulhouse #louisvega #mastersatwork #maw #jerseyhousemusic #jerseyhouse #welovehousemusic (at United States of America) https://www.instagram.com/p/B_EVOIylzin/?igshid=1vk0i6q6iaaux

[cancersfakianakis1]

Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score

Publication date: November 2017 Source:European Journal of Cancer, Volume 86 Author(s): J. Edeline, J.-F. Blanc, B. Campillo-Gimenez, Y.-T. Ma, J. King, O. Faluyi, J. Mathurin, S. Ghazi, D.H. Palmer, T. Meyer BackgroundNo prognostic classification is currently used for patients treated with systemic therapies for Hepatocellular Carcinoma (HCC).MethodsWe retrospectively analysed data from patients treated with sorafenib for HCC from five centres in France and in the United Kingdom (UK). The training set comprised data from two centres and the validation set from three. Variables independently associated with Overall Survival (OS) in the training set were used to build the SAP (Sorafenib Advanced HCC Prognosis) score. The score was tested in the validation set, then compared with other prognostication systems.ResultsThe training set and validation set included 370 and 468 patients respectively. In the training set, variables independently associated with OS in multivariable analysis were: performance status (PS) >0, alpha-fetoprotein (AFP) >400 ng/ml, tumour size >7 cm, bilirubin >17 μmol/l and albumin <36 g/l. The SAP score was built giving one point to each abnormal variable, and three classes were constructed. The SAP score was significantly associated with OS in the training set, with median OS of 14.9 months for SAP A, 7.2 months for SAP B and 2.5 months for SAP C (P < 0.001). In the validation set, the SAP score was significantly associated with OS, and showed greater discriminative abilities than Barcelona Clinic Liver Cancer (BCLC) and albumin-bilirubin (ALBI) scores. However, the hepatoma arterial embolisation prognostic (HAP) score showed greater discriminative abilities than the SAP score.ConclusionIn European patients treated with sorafenib, the HAP was the most discriminant prognostic score and may facilitate stratification in trials and inform clinical decision making. http://ift.tt/2hOkWg7

[vinos-tb]

no-repeat center fixed;  background-size: cover;   background-attachment: scroll;

no-repeat center fixed;

backgroundno-repeat center fixed;

background-size: cover;

background-attachment: scroll;-size: cover;

background-attachment: scroll;

[cancersfakianakis1]

Colorectal cancer metastatic disease progression in Australia: A population-based analysis

Publication date: August 2017 Source:Cancer Epidemiology, Volume 49 Author(s): Qingwei Luo, Dianne L. O’Connell, Clare Kahn, Xue Qin Yu BackgroundNo previous Australian population-based studies have described or quantified the progression of colorectal cancer (CRC) to metastatic disease. We describe patterns of progression to metastatic disease for an Australian cohort diagnosed with localised or regional CRC.MethodsAll localised and regional CRC cases in the New South Wales Cancer Registry diagnosed during 2000–2007 were followed to December 2011 for subsequent metastases (identified by subsequent disease episode notifications) or CRC death. Cox regression was used to identify factors associated with metastatic progression.ResultsAfter a median 5.3 years follow-up, 26.4% of the 12757 cases initially diagnosed with localised or regional colon cancer had developed metastatic disease, as had 29.5% of the 7154 rectal cancer cases. For both cancer sites, risk of metastatic progression was significantly higher for those initially diagnosed with regional disease (adjusted hazard ratio [aHR] 3.49 for colon, 2.66 for rectal cancer), and for older cases (e.g. aHR for >79years vs <60years: 1.38 for colon, 1.69 for rectal cancer). Risk of disease progression was significantly lower for females, and varied by histology type. For colon cancer, the risk of disease progression decreased over time. For rectal cancer, risk of metastatic progression was significantly higher for those living in more socioeconomically disadvantaged areas compared with those in the least disadvantaged area.ConclusionsAn understanding of the variation in risk of metastatic progression is useful for planning health service requirements, and can help inform decisions about treatment and follow-up for colorectal cancer patients. http://ift.tt/2qZLn61